Cue Biopharma/$CUE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cue Biopharma
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
Ticker
$CUE
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
41
ISIN
US22978P1066
Website
Cue Biopharma Metrics
BasicAdvanced
$51M
-
-$0.65
1.51
-
Price and volume
Market cap
$51M
Beta
1.51
52-week high
$1.75
52-week low
$0.45
Average daily volume
247K
Financial strength
Current ratio
1.028
Quick ratio
0.906
Long term debt to equity
2.675
Total debt to equity
108.283
Interest coverage (TTM)
-60.36%
Profitability
EBITDA (TTM)
-40.825
Gross margin (TTM)
-333.53%
Net profit margin (TTM)
-507.87%
Operating margin (TTM)
-515.88%
Revenue per employee (TTM)
$190,000
Management effectiveness
Return on assets (TTM)
-67.62%
Return on equity (TTM)
-221.66%
Valuation
Price to revenue (TTM)
5.339
Price to book
6.41
Price to tangible book (TTM)
6.41
Price to free cash flow (TTM)
-1.223
Free cash flow yield (TTM)
-81.76%
Free cash flow per share (TTM)
-55.78%
Growth
Revenue change (TTM)
13.83%
Earnings per share change (TTM)
-39.01%
3-year revenue growth (CAGR)
-17.80%
3-year earnings per share growth (CAGR)
-23.36%
What the Analysts think about Cue Biopharma
Analyst ratings (Buy, Hold, Sell) for Cue Biopharma stock.
Cue Biopharma Financial Performance
Revenues and expenses
Cue Biopharma Earnings Performance
Company profitability
Cue Biopharma News
AllArticlesVideos
Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies
GlobeNewsWire·2 hours ago
Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company's Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease
GlobeNewsWire·1 week ago
Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cue Biopharma stock?
Cue Biopharma (CUE) has a market cap of $51M as of July 01, 2025.
What is the P/E ratio for Cue Biopharma stock?
The price to earnings (P/E) ratio for Cue Biopharma (CUE) stock is 0 as of July 01, 2025.
Does Cue Biopharma stock pay dividends?
No, Cue Biopharma (CUE) stock does not pay dividends to its shareholders as of July 01, 2025.
When is the next Cue Biopharma dividend payment date?
Cue Biopharma (CUE) stock does not pay dividends to its shareholders.
What is the beta indicator for Cue Biopharma?
Cue Biopharma (CUE) has a beta rating of 1.51. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.